本报记者 柴嵘 "渐冻人""瓷娃娃""蝴蝶宝贝"，这些"美丽"名字的背后，分别对应着肌萎缩侧索硬化症、成骨不全症、大疱性表皮松解症。这些疾病被统称为罕见病，世界 卫生组织将其定义为患病人数占总人口0.065%至0.1%之间的疾病。 每个周四，北京协和医院疑难罕见病会诊中心，来自神经科、儿科、遗传咨询室、放射科等十余个科室的顶尖专家围坐一堂，讨论病情、分析病历。他们研 判的可能是一种全球仅报告过几十例的罕见病，也可能是一个让家庭跑遍全国、花了十多年仍无解的医学难题。 "健康中国的路上，一个都不能少。" 这是北京协和医院院长张抒扬常说的一句话，也是她和团队十多年来的工作信条。面对这片医学的"无人区"，他们正努力搭建一套从诊断到治疗、从医院到 全国的系统，为那些生命孤岛点亮一盏灯。 2025年2月27日，第281场罕见病多学科会诊举行。 1 编织协作网 长期以来，诊断难、治疗难、用药难像三座大山，横亘在罕见病患者面前。先得到一个明确诊断，对许多人来说都是一种奢望。罕见病患者症状复杂，常涉 及多个学科，而具备诊断经验和能力的医生太少。 "医生，我的孩子到底得了什么病？"这样的问题，张抒扬听过太多遍，她感慨："过去有个 ...

人勤春来早，奋进正当时。2月24日，长沙市持续用力打造"三个高地"加快推进高质量发展会议 上，对打造具有核心竞争力的科技创新高地、纵深推进全球研发中心城市建设、进一步推动科产融合发 展重点工作进行了部署，并现场印发《长沙市打造具有核心竞争力的科技创新高地暨全球研发中心城市 建设2026年行动方案》（以下简称《行动方案》），明确了全年科技创新工作的重点和目标。 此外，着眼长远，加快布局研发平台。围绕先进计算、空天海洋、创新药等关键领域，布局建设一批高 水平市级科技创新平台。推进湘江创新馆、上海交通大学湖南高等研究院、湖南钢铁技术研究院等重大 项目建设。强化高能级平台"一对一"服务体系，加速成果转化。力争新增"三类500强"、领军企业研发 中心5家左右；符合"四个全球"定位特征（功能布局基于全球、研发任务源自全球、研发资源来自全 球、研发成果用于全球）的科技创新平台占比达到15%。 抓科产融合，强化科技赋能 "推动科技创新和产业创新深度融合"，是《中共中央关于制定国民经济和社会发展第十五个五年规划的 建议》提出的重大任务。《行动方案》因地制宜进行谋划，推动科创与产业同频共振、双向赋能。 强化关键技术攻关，增加高质 ...

Core Viewpoint - The joint measures issued by multiple government departments aim to cultivate the elderly care service industry and promote the silver economy, ensuring fair competition and market vitality in the sector [1][3]. Group 1: Brand Development - Support for the establishment of distinctive branding for chain elderly care service providers to enhance brand recognition [4]. - Encouragement for elderly care service providers to implement trademark strategies and protect their brands [4]. - Promotion of quality elderly care brands through various initiatives to create leading enterprises in the sector [4]. Group 2: Market Supply and Demand - Optimization of elderly care services and products to meet community needs, including home care services and specialized medical assistance [6]. - Development of platforms for supply and demand matching in the elderly care market, enhancing resource utilization and facilitating connections among stakeholders [6]. Group 3: Technological Empowerment - Encouragement for technological advancements in elderly care, including the use of AI, big data, and robotics to enhance service delivery [7]. - Support for the application and testing of smart elderly care products within service institutions to improve user experience [7]. Group 4: Development Environment Optimization - Creation of a fair competitive environment by prohibiting restrictive clauses in government procurement processes for elderly care services [8]. - Establishment of standards and certification systems for elderly care products and services to ensure quality and safety [8]. Group 5: Support Measures - Improvement of government services for elderly care providers, including streamlined licensing processes and access to information on policies and resources [11]. - Provision of land and operational support for elderly care facilities, prioritizing areas based on local aging population needs [11].

Core Viewpoint - Exegenesis Bio Inc. has submitted its listing application to the Hong Kong Stock Exchange, with CCB International acting as the sole sponsor, highlighting its innovative AAVarta and SODA technology platforms for developing a diverse and scalable product pipeline [1]. Group 1: Company Overview - Exegenesis Bio Inc. is registered in the Cayman Islands and is focused on biotechnology [2]. - The company is developing core candidate products, including EXG001-307 for SMA type 1, along with two key candidates, EXG102-031 and EXG202 [1]. Group 2: Financial Details - The company has set a nominal value of $0.00001 per share for its stock [2]. - Additional costs associated with the share issuance include a 1.0% brokerage commission, transaction fees from the Securities and Futures Commission, and other exchange-related fees [2].

Group 1: Photovoltaic Industry - The export tax rebate for photovoltaic products will be fully canceled starting April 1, 2026, increasing export costs for companies [2] - The export tax rebate for photovoltaic silicon wafers, batteries, and modules was previously reduced from 13% to 9% in December 2024, indicating a trend of declining export tax rates [2] - The Chinese photovoltaic industry has seen a decrease in export prices since 2024, leading to a "volume increase, price decrease" situation, with some companies passing on rebate amounts to foreign buyers, resulting in profit loss [2][3] - The cancellation of export tax rebates aims to promote rational competition in the photovoltaic industry and curb excessive price declines [3] Group 2: Elderly Care Robotics - Eight departments, including the Ministry of Civil Affairs, have issued measures to encourage the development of the elderly care robotics industry, promoting technological integration across various sectors [4] - The initiative aims to provide comprehensive intelligent support for the elderly, leveraging technologies such as embodied intelligence and new materials [4][5] - The market for elderly care technology products and services is expected to expand rapidly, although current technology maturity remains insufficient [5] Group 3: Real Estate Market in Tianjin - Tianjin will tighten control over new housing prices, limiting price changes to within 10% of the registered price for new sales permits [6] - The city has previously implemented price control measures to stabilize housing prices, with over 20 cities having introduced similar "price drop limits" [6][7] - The new management approach aims to control both price increases and decreases, although enforcing price decreases may face challenges [6] Group 4: AI and Technology Collaborations - Google and Apple have entered a strategic partnership, with Google's Gemini model being used to support Apple's AI developments, including Siri [8] - Apple is expected to pay approximately $1 billion annually to Google for technology licensing, indicating a significant investment in AI capabilities [8] - Nvidia and Eli Lilly have announced a $1 billion collaboration to establish a research lab focused on AI applications in the pharmaceutical industry, highlighting the growing intersection of AI and healthcare [10][11] Group 5: ByteDance's Stock Options - ByteDance's stock option price has increased from $44 in 2019 to $226.07 in January 2024, representing a rise of over 4 times [14] - The company is reportedly raising its valuation to between $350 billion and $370 billion as it continues to enhance employee compensation and stock option incentives [14][15] - ByteDance's strong financial performance and aggressive AI application strategy position it as a leading player in the tech industry, despite facing increasing policy risks in overseas markets [15]

Group 1 - The government is promoting the integration of technology in elderly care services, emphasizing the use of big data, cloud computing, artificial intelligence, and other advanced technologies for health monitoring and personalized services [1] - There is a strong growth in the silver economy, particularly in industries catering to both disabled and semi-disabled individuals, as well as active elderly consumers, driven by advancements in AI, robotics, and IoT [2] - Companies are focusing on rehabilitation and elderly care services, with significant investments planned in smart elderly care projects to capitalize on the silver economy [3] Group 2 - The development of smart and digital products for the elderly is a primary focus, with companies creating multi-layered, scenario-based smart elderly care products and services [4] - Companies are launching various rehabilitation robots and smart solutions for elderly care, with ongoing pilot tests in real-life scenarios [5] - Cross-industry collaborations are emerging, with companies in education and real estate exploring opportunities in the silver economy to enhance their service offerings [6]

Core Viewpoint - The Ministry of Civil Affairs and eight other departments have jointly issued measures to stimulate the vitality of various elderly care service providers, create a favorable investment environment, and promote the development of the silver economy to better meet the diverse needs of the elderly [1][3] Group 1: Policy Measures - The measures aim to optimize the supply of elderly care services and age-friendly products, encouraging community-based operations and integration of resources to enhance service delivery [4] - The initiative supports the development of home care services for the elderly, including professional medical accompaniment and mobile bathing services [4] - There is a focus on promoting smart rehabilitation aids and age-appropriate food and clothing products, enhancing the living environment for the elderly [4] Group 2: Market Dynamics - By the end of 2025, there will be 41,700 elderly care institutions in China, with 722,000 employees, reflecting a 12.2% year-on-year increase, and 52.2% of these institutions will be privately owned [5] - Social forces are becoming the main contributors to the diversified supply of elderly care services, indicating a shift in the service landscape [5] Group 3: Technological Support - The measures encourage technological advancements in elderly care, integrating big data, AI, and other technologies for health monitoring and personalized services [6] - There is a push for the development of elderly care robots and smart home technologies to meet the daily care and emotional support needs of the elderly [6] - The market is expected to see new opportunities driven by the integration of technology in elderly care, with a focus on smart home products and AI solutions [7]

Core Insights - The global biopharmaceutical industry is undergoing unprecedented transformation driven by advancements in artificial intelligence, genetic technology, and synthetic biology [1] Group 1: Strengths - The UK pharmaceutical industry benefits from a strong scientific foundation and an evolving data ecosystem, with the UK Biobank being a valuable asset containing detailed genetic and health data from 500,000 volunteers [1] - The close proximity of universities and pharmaceutical companies in the Cambridge Biomedical Campus facilitates technology transfer and reduces friction costs [2] - The UK Medicines and Healthcare products Regulatory Agency has been praised for its agility, having doubled the speed of clinical trial approvals through AI and digital transformation, allowing some low-risk studies to be approved in as little as 14 days [2] Group 2: Challenges - Emerging technologies are reshaping the biopharmaceutical industry, with AI and biotechnology accelerating drug development, yet the industry faces fundamental challenges due to regulatory adjustments post-Brexit and structural issues within the National Health Service [3] - Companies like GlaxoSmithKline struggle to convert vast amounts of genetic data into viable drug targets, facing obstacles in obtaining high-quality clinical data due to privacy concerns and fragmented data systems [3] Group 3: Constraints - The UK pharmaceutical industry is experiencing structural barriers in commercialization, described as "strong in science, weak in business," with companies like Merck announcing the closure of labs in London due to a lack of progress in life sciences investment [4] - Many startups in the Cambridge Biomedical Campus are being acquired by American firms due to a lack of risk-taking investors in the UK, leading to funding challenges during critical growth phases [5] - The National Health Service's policies limit the pricing and approval processes for innovative drugs, compounded by the bureaucratic challenges of Brexit, which slow down supply chain responses and hinder the recruitment of top EU talent [5]

Core Viewpoint - The UK pharmaceutical industry is at a critical juncture, facing the challenge of either leading a new wave of industrial transformation or becoming marginalized in the face of intense competition driven by advancements in artificial intelligence, genetic technology, and synthetic biology [1] Group 1: Strengths - The UK pharmaceutical industry benefits from a strong scientific foundation and a well-developed data ecosystem, with the UK Biobank being a valuable asset containing detailed genetic and health data from 500,000 volunteers, making it a global hub for drug target discovery [1] - The close collaboration between universities and pharmaceutical companies in the UK, exemplified by the Cambridge Biomedical Campus, reduces friction costs in technology transfer, facilitating innovation [2] - The UK Medicines and Healthcare products Regulatory Agency has been praised for its agility, having doubled the speed of clinical trial approvals through digital transformation, allowing some low-risk studies to be approved within 14 days [2] Group 2: Challenges - The integration of emerging technologies is reshaping the global biopharmaceutical industry, but the UK faces challenges in adapting to these changes, particularly in converting vast amounts of genetic data into viable drug targets [3] - Internal pressures, such as regulatory adjustments post-Brexit and structural issues within the National Health Service, hinder innovation in the UK pharmaceutical sector [3] - The UK pharmaceutical industry is described as having strong scientific capabilities but weak commercialization, with major companies like Merck announcing the closure of labs in London due to a lack of progress in life sciences investment [4] Group 3: Market Constraints - Many UK startups are being acquired by American companies due to a lack of risk-taking investors in the UK, leading to funding challenges during critical growth phases [4] - The National Health Service's policies limit the market entry of innovative drugs, with low reimbursement prices and slow approval processes affecting the efficiency and commercial returns of new drug launches [4] - Post-Brexit, increased non-tariff barriers have slowed supply chain responsiveness, and restrictions on the free movement of European scientists have made it harder for UK labs to recruit top talent [5]

Group 1 - The China-Italy Eye Health Innovation Cooperation event was held in Beijing, focusing on practical cooperation in the eye health sector between China and Italy [1] - He Eye Hospital, a technology-driven listed company, aims to create a comprehensive ecosystem for eye health through its "Smart Light City" strategy, integrating AI, genetic technology, and regenerative medicine [1] - The collaboration emphasizes research and product development in key areas such as refractive cataracts, myopia prevention in youth, and dry eye treatment, aiming to provide Chinese patients with access to top global eye health products and services [1] Group 2 - He Eye Hospital has been dedicated to the eye health field for 30 years, combining technological innovation with public welfare services to create a new ecosystem for eye health [2] - The "three-tier eye health medical service model" developed by He Eye Hospital has gained industry recognition as a replicable and sustainable public health model [2] - The successful event marks an important step for He Eye Hospital in promoting international cooperation in eye health and aims to enhance the quality of eye health services through ongoing international collaboration [2]